First Direct Comparison of the Late Sodium Current Blocker Ranolazine to Established Antiarrhythmic Agents in an Ischemia/Reperfusion Model

Abstract

Introduction: There are few safe antiarrhythmics for ischemic heart disease. Whereas ranolazine is a promising late INa blocker with antiarrhythmic effects, and devoid of pro-arrhythmic properties, there are no direct comparisons between ranolazine and other antiarrhythmic agents in an ischemia/reperfusion setting. Hypothesis and methods: To determine whether ranolazine was as effective as sotalol and lidocaine to reduce ischemia/reperfusion-induced arrhythmias, anesthetized rats were subjected to 5 minutes of proximal left coronary artery occlusion plus 5 minutes of reperfusion, which causes severe ventricular arrhythmias. At 21 minutes prior to coronary occlusion, rats (n = 20 per group) were randomized to receive either sotalol (intravenous [IV] bolus 5 mg/kg, 10 mg/kg per hour infusion), lidocaine (IV bolus 2.5 mg/kg, 2.5 mg/kg/hr infusion), ranolazine (IV bolus 3.3 mg/kg, 3.2 mg/kg per hour infusion), or saline (control). Results: The incidence of ventricular arrhythmias in the sotalol (S), lidocaine (L), ranolazine (R), and control (C) groups was 7/20, 10/20, 9/20, and 16/20, respectively (P = .01 S vs C, P = .10 L vs C, and P = .048 R vs C). Duration of ventricular tachycardia (VT) episodes was reduced from 15.5 seconds (mean) in C to 1.3 seconds in S, 1.4 sec in L and 0.09 sec in R (P < .05 for S vs C and R vs C by Wilcoxon test). The number of rats with any (≥10 seconds) sustained VT was 3 in C versus 1, 0, and 0 in the S, L, and R groups, respectively. Two rats in C had reversible ventricular fibrillation versus 0 in the S, L, and R groups. The number of ventricular premature beats (VPBs) per rat was 10.9 in C, 2.3 in S, 4.9 in L, and 5.7 in R (P < .05 for S, L, or R vs C). P = NS for R versus L or S for all analyses. Conclusion: In this first head-to-head comparison of R vs other antiarrhythmic agents at therapeutic doses in an ischemia/reperfusion model, ranolazine (which lacks pro-arrhythmic effects) was as effective as either sotalol or lidocaine to reduce reperfusion-induced ventricular arrhythmias.

Keywords

arrhythmias ischemia/reperfusion ranolazine late sodium current inhibitor ventricular tachycardia

References

Chaitman BR , Skettino SL , Parker JO , et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375-1382.

Foster NJ , Haines DE The Antiarrhythmic Effects of Ranolazine. Rev Cardiovasc Med. 2009;10(suppl1):S38-S45.

Dhalla AK , Wang WQ , Dow J. , et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297(5):H1923-H1929.

Kloner RA , Dow J. , Bhandari A. The anti-anginal agent ranolazine is a potent anti-arrhythmic agent that reduces ventricular arrhythmias through a mechanism favoring inhibition of late sodium channel. Cardiovasc Ther. 2010. In press.

Antzelevitch C. , Belardinelli L. , Zygmunt AC , et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904-910.

Hagar JM , Hale SL , Kloner RA Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res. 1991;68(1):61-68.

Kloner RA , Dow J. Bhandari A. Postconditioning markedly attenuates ventricular arrhythmias after ischemia reperfusion. J Cardiovasc Pharmacol Ther. 2006;11(1):55-63.

Dow J. , Bhandari A. , Kloner RA Ischemic postconditioning’s benefit on reperfusion ventricular arrhythmias is maintained in the senescent heart. J Cardiovasc Pharmacol Ther. 2008;13(2):141-148.

Ohara F. , Sugimoto T. , Yamamoto N. , et al. Protective effect of FR168888, a New Na+/H+ exchange inhibitor, on ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats: in comparison with other cardioprotective compounds. Jpn J Pharmacol. 1999;80(4):295-302.

10.

Lu HR , Yang P. , Remeysen P. , Saels A. , Dai DZ , De Clerck F. Ischemia/reperfusion-induced arrhythmias in anesthetized rats: a role of Na+ and Ca2+ influx. Eur J Pharmacol. 1999;365(2-3):233-239.

11.

Knudsen K. , Abrahamsson J. Effects of magnesium sulfate and lidocaine in the treatment of ventricular arrhythmias in experimental amitriptyline poisoning in the rat. Crit Care Med. 1994; 22(3):494-498.

12.

Lamontagne D. , Rochette L. , Vermeulen M. , Yamaguchi N. , Nadeau R. , De Champlain J. Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar Rats. Fundam Clin Pharmacol. 1989;3(6):671-685.

13.

Hashimoto K. , Haruno A. , Hirasawa A. , Awaji T. , Xue Y. , Wu Z. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. Jpn J Pharmacol. 1995;68(1):1-9.

14.

Scirica BM , Morrow DA , Hod H. , et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patient with non-ST-segment-elevation acute coronary syndrome. Result from the metabolic efficacy with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647-1652.

15.

Hale SL , Belardinelli L. , Shryock JC , Sweeney M. , Kloner RA Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiology. 2008;44(6):954-967.

16.

Reffelmann T. , Kloner RA Ranolazine-an antianginal-drug with further therapeutic potential. Expert Rev Cardiovasc Ther. 2010; 8(3):319-329.

17.

Hwang H. , Arcidi J. , Hale SL , et al. Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. J Cardiovasc Pharmacol Ther. 2009;14(2):125-133.

18.

Hwang H. , Arcidi JM , Hale SL , et al. Ranolazine as cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation. 2009;120(11suppl):S16-S21.

19.

Camm JA , Al-Saady NM , Opie LH Antiarrhythmic agents. In: Opie LH , Gersh BJ , eds. Drugs for the Heart. 5th ed. Philadelphia, PA: W. B. Saunders Company; 2001:221-272.

20.

Hale SL , Leeka JA , Kloner RA Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium current . J Pharmacol Exp Ther. 2006;318(1): 428-423.